Review





Similar Products

94
TargetMol anti mouse cd8 α antibody
Anti Mouse Cd8 α Antibody, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd8/Anti-mouse+CD8%CE%B1+Antibody/pm42839693-256-9-23
Average 94 stars, based on 1 article reviews
anti mouse cd8 α antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Bio X Cell anti cd8
( A ) In vivo tumor growth of RP-sgCtrl and RP-sg Crebbp cells in nude mice, with quantification of tumor weights at the endpoint (n = 6 per group). ( B ) In vivo tumor growth of RP-sgCtrl and RP-sg Crebbp cells in C57BL/6 mice, with quantification of tumor weights at the endpoint (n = 6 per group). ( C ) In vivo tumor growth of RP-shCtrl and RP-sh Crebbp cells in nude mice, with quantification of tumor weights at the endpoint (n = 5 per group). ( D ) In vivo tumor growth of RP-shCtrl and RP-sh Crebbp cells in C57BL/6 mice, with quantification of tumor weights at the endpoint (n = 4 for RP-shNS, n = 5 for each RP-sh Crebbp cell). ( E to G ) Flow cytometry analysis of <t>CD8</t> + T cell proportions (E), CD44 hi CD62L lo CD8+ T cell proportions (F), and IFNγ + CD8 + T cell proportions (G) in allograft tumors formed by RP-sgCtrl and RP-sg Crebbp cells in C57BL/6 mice. n = 6 per group. ( H ) In vivo growth of RP-sgCtrl and RP-sg Crebbp cells in C57BL/6 mice treated with IgG control or <t>anti-CD8</t> antibodies, with quantification of tumor weights at the endpoint (n = 5 per group). ( I ) Flow cytometry analysis of apoptotic RP-OVA, RP-OVA-shCtrl, and RP-OVA-sh Crebbp -1 tumor cells, with or without co-culture with OT-1 CD8 + T cells. Quantification of the apoptotic tumor cell proportions is shown (right). [(A), (B), (C), (D), and (H)] Two-way ANOVA test for tumor growth curves and unpaired Student’s t test for tumor weights. *** P < 0.001; **** P < 0.0001. ns, not significant. Data were shown as mean ± SEM. [(E) to (G) and (I)] Unpaired Student’s t test; * P < 0.05; ** P < 0.01. Data were shown as mean ± SD.
Anti Cd8, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd8/InVivoMAb+anti-mouse+CD8%CE%B2/pmc13685914-168-17-19
Average 96 stars, based on 1 article reviews
anti cd8 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech anti cd8 mouse monoclonal antibody
Characterization of KRAS G12V-BsAb. ( A–B ) Selective binding of the purified scDb2 to KRAS G12V/HLA-A*11:01 ( A ) and CD3 ( B ) by ELISA. Biotinylated KRAS G12V/HLA-A*11:01 or recombinant CD3ε/δ was coated on a streptavidin plate and then incubated with scDb2 at 0.1, 1 or 10 nM, followed by detection with an anti-His antibody. Optical density at 450 nm was measured on a spectrophotometric plate reader. Data represent mean±SD of three technical replicates. ( C ) Surface plasmon resonance analysis of scDb2 binding to KRAS G12V/HLA-A*11:01 and KRAS WT/HLA-A*11:01. Binding kinetics were determined by fitting to a 1:1 Langmuir model. ( D ) Dose-dependent T-cell activation by scDb2. C1R-A11 cells pulsed with KRAS G12V or WT peptides were co-cultured with <t>CD8</t> + T cells in the presence of increasing concentrations (0, 0.1, 0.3, 1 and 10 nM) of scDb2. IFN-γ secretion was quantified by ELISpot assay. Data represent mean±SD of three technical replicates. The EC 50 for IFN-γ secretion was 0.59 nM for C1R-A11 cells. p=0.0023 at 0.3 nM and p<0.0001 at 1 and 10 nM versus KRAS WT (Tukey’s test). ( E ) KRAS peptide-specific T-cell activation by scDb2. C1R-A11 cells were pulsed with different KRAS G12 variant peptides (WT, G12A, G12C, G12D, G12R and G12S), then co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. IFN-γ secretion was measured by ELISpot. Data represent mean±SD of three technical replicates. p<0.0001 versus no peptide (Dunnett’s test). ( F ) HLA-restricted T-cell activation by scDb2. C1R cells expressing a panel of prevalent HLA-A alleles (HLA-A*02:01, HLA-A*02:06, HLA-A*03:01, HLA-A*11:01, HLA-A*24:02, HLA-A*31:01 and HLA-A*33:03) were pulsed with KRAS G12V peptide and co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. Data represent mean±SD of three technical replicates. p<0.0001 for HLA-A*11:01 and HLA-A*03:01 versus the no-peptide control; no significant differences were observed for the other HLA alleles versus the no-peptide control (Dunnett’s test). BsAb, bispecific antibody; EC 50 , half-maximal effective concentrations; ELISpot, enzyme-linked immunosorbent spot; HLA, human leukocyte antigen; IFN, interferon; scDb, single-chain diabody; WT, wild-type.
Anti Cd8 Mouse Monoclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd8/KI67+Antibody/pmc13691759-93-7-11
Average 96 stars, based on 1 article reviews
anti cd8 mouse monoclonal antibody - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

97
Bio X Cell anti mouse cd8 antibody
Characterization of KRAS G12V-BsAb. ( A–B ) Selective binding of the purified scDb2 to KRAS G12V/HLA-A*11:01 ( A ) and CD3 ( B ) by ELISA. Biotinylated KRAS G12V/HLA-A*11:01 or recombinant CD3ε/δ was coated on a streptavidin plate and then incubated with scDb2 at 0.1, 1 or 10 nM, followed by detection with an anti-His antibody. Optical density at 450 nm was measured on a spectrophotometric plate reader. Data represent mean±SD of three technical replicates. ( C ) Surface plasmon resonance analysis of scDb2 binding to KRAS G12V/HLA-A*11:01 and KRAS WT/HLA-A*11:01. Binding kinetics were determined by fitting to a 1:1 Langmuir model. ( D ) Dose-dependent T-cell activation by scDb2. C1R-A11 cells pulsed with KRAS G12V or WT peptides were co-cultured with <t>CD8</t> + T cells in the presence of increasing concentrations (0, 0.1, 0.3, 1 and 10 nM) of scDb2. IFN-γ secretion was quantified by ELISpot assay. Data represent mean±SD of three technical replicates. The EC 50 for IFN-γ secretion was 0.59 nM for C1R-A11 cells. p=0.0023 at 0.3 nM and p<0.0001 at 1 and 10 nM versus KRAS WT (Tukey’s test). ( E ) KRAS peptide-specific T-cell activation by scDb2. C1R-A11 cells were pulsed with different KRAS G12 variant peptides (WT, G12A, G12C, G12D, G12R and G12S), then co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. IFN-γ secretion was measured by ELISpot. Data represent mean±SD of three technical replicates. p<0.0001 versus no peptide (Dunnett’s test). ( F ) HLA-restricted T-cell activation by scDb2. C1R cells expressing a panel of prevalent HLA-A alleles (HLA-A*02:01, HLA-A*02:06, HLA-A*03:01, HLA-A*11:01, HLA-A*24:02, HLA-A*31:01 and HLA-A*33:03) were pulsed with KRAS G12V peptide and co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. Data represent mean±SD of three technical replicates. p<0.0001 for HLA-A*11:01 and HLA-A*03:01 versus the no-peptide control; no significant differences were observed for the other HLA alleles versus the no-peptide control (Dunnett’s test). BsAb, bispecific antibody; EC 50 , half-maximal effective concentrations; ELISpot, enzyme-linked immunosorbent spot; HLA, human leukocyte antigen; IFN, interferon; scDb, single-chain diabody; WT, wild-type.
Anti Mouse Cd8 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd8/InVivoMAb+anti-mouse+CD8%CE%B1/pm42875754-77-10-13
Average 97 stars, based on 1 article reviews
anti mouse cd8 antibody - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

95
Bio-Rad antibovine cd28 antibody
Characterization of KRAS G12V-BsAb. ( A–B ) Selective binding of the purified scDb2 to KRAS G12V/HLA-A*11:01 ( A ) and CD3 ( B ) by ELISA. Biotinylated KRAS G12V/HLA-A*11:01 or recombinant CD3ε/δ was coated on a streptavidin plate and then incubated with scDb2 at 0.1, 1 or 10 nM, followed by detection with an anti-His antibody. Optical density at 450 nm was measured on a spectrophotometric plate reader. Data represent mean±SD of three technical replicates. ( C ) Surface plasmon resonance analysis of scDb2 binding to KRAS G12V/HLA-A*11:01 and KRAS WT/HLA-A*11:01. Binding kinetics were determined by fitting to a 1:1 Langmuir model. ( D ) Dose-dependent T-cell activation by scDb2. C1R-A11 cells pulsed with KRAS G12V or WT peptides were co-cultured with <t>CD8</t> + T cells in the presence of increasing concentrations (0, 0.1, 0.3, 1 and 10 nM) of scDb2. IFN-γ secretion was quantified by ELISpot assay. Data represent mean±SD of three technical replicates. The EC 50 for IFN-γ secretion was 0.59 nM for C1R-A11 cells. p=0.0023 at 0.3 nM and p<0.0001 at 1 and 10 nM versus KRAS WT (Tukey’s test). ( E ) KRAS peptide-specific T-cell activation by scDb2. C1R-A11 cells were pulsed with different KRAS G12 variant peptides (WT, G12A, G12C, G12D, G12R and G12S), then co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. IFN-γ secretion was measured by ELISpot. Data represent mean±SD of three technical replicates. p<0.0001 versus no peptide (Dunnett’s test). ( F ) HLA-restricted T-cell activation by scDb2. C1R cells expressing a panel of prevalent HLA-A alleles (HLA-A*02:01, HLA-A*02:06, HLA-A*03:01, HLA-A*11:01, HLA-A*24:02, HLA-A*31:01 and HLA-A*33:03) were pulsed with KRAS G12V peptide and co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. Data represent mean±SD of three technical replicates. p<0.0001 for HLA-A*11:01 and HLA-A*03:01 versus the no-peptide control; no significant differences were observed for the other HLA alleles versus the no-peptide control (Dunnett’s test). BsAb, bispecific antibody; EC 50 , half-maximal effective concentrations; ELISpot, enzyme-linked immunosorbent spot; HLA, human leukocyte antigen; IFN, interferon; scDb, single-chain diabody; WT, wild-type.
Antibovine Cd28 Antibody, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd8/Mouse+anti+Bovine+CD8/pm42855056-78-28-32
Average 95 stars, based on 1 article reviews
antibovine cd28 antibody - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Selleck Chemicals anti cd8
Characterization of KRAS G12V-BsAb. ( A–B ) Selective binding of the purified scDb2 to KRAS G12V/HLA-A*11:01 ( A ) and CD3 ( B ) by ELISA. Biotinylated KRAS G12V/HLA-A*11:01 or recombinant CD3ε/δ was coated on a streptavidin plate and then incubated with scDb2 at 0.1, 1 or 10 nM, followed by detection with an anti-His antibody. Optical density at 450 nm was measured on a spectrophotometric plate reader. Data represent mean±SD of three technical replicates. ( C ) Surface plasmon resonance analysis of scDb2 binding to KRAS G12V/HLA-A*11:01 and KRAS WT/HLA-A*11:01. Binding kinetics were determined by fitting to a 1:1 Langmuir model. ( D ) Dose-dependent T-cell activation by scDb2. C1R-A11 cells pulsed with KRAS G12V or WT peptides were co-cultured with <t>CD8</t> + T cells in the presence of increasing concentrations (0, 0.1, 0.3, 1 and 10 nM) of scDb2. IFN-γ secretion was quantified by ELISpot assay. Data represent mean±SD of three technical replicates. The EC 50 for IFN-γ secretion was 0.59 nM for C1R-A11 cells. p=0.0023 at 0.3 nM and p<0.0001 at 1 and 10 nM versus KRAS WT (Tukey’s test). ( E ) KRAS peptide-specific T-cell activation by scDb2. C1R-A11 cells were pulsed with different KRAS G12 variant peptides (WT, G12A, G12C, G12D, G12R and G12S), then co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. IFN-γ secretion was measured by ELISpot. Data represent mean±SD of three technical replicates. p<0.0001 versus no peptide (Dunnett’s test). ( F ) HLA-restricted T-cell activation by scDb2. C1R cells expressing a panel of prevalent HLA-A alleles (HLA-A*02:01, HLA-A*02:06, HLA-A*03:01, HLA-A*11:01, HLA-A*24:02, HLA-A*31:01 and HLA-A*33:03) were pulsed with KRAS G12V peptide and co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. Data represent mean±SD of three technical replicates. p<0.0001 for HLA-A*11:01 and HLA-A*03:01 versus the no-peptide control; no significant differences were observed for the other HLA alleles versus the no-peptide control (Dunnett’s test). BsAb, bispecific antibody; EC 50 , half-maximal effective concentrations; ELISpot, enzyme-linked immunosorbent spot; HLA, human leukocyte antigen; IFN, interferon; scDb, single-chain diabody; WT, wild-type.
Anti Cd8, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd8/Anti-mouse+CD8%CE%B1-InVivo/pm42833217-307-14-17
Average 95 stars, based on 1 article reviews
anti cd8 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Bio X Cell anti mouse cd8 α
Characterization of KRAS G12V-BsAb. ( A–B ) Selective binding of the purified scDb2 to KRAS G12V/HLA-A*11:01 ( A ) and CD3 ( B ) by ELISA. Biotinylated KRAS G12V/HLA-A*11:01 or recombinant CD3ε/δ was coated on a streptavidin plate and then incubated with scDb2 at 0.1, 1 or 10 nM, followed by detection with an anti-His antibody. Optical density at 450 nm was measured on a spectrophotometric plate reader. Data represent mean±SD of three technical replicates. ( C ) Surface plasmon resonance analysis of scDb2 binding to KRAS G12V/HLA-A*11:01 and KRAS WT/HLA-A*11:01. Binding kinetics were determined by fitting to a 1:1 Langmuir model. ( D ) Dose-dependent T-cell activation by scDb2. C1R-A11 cells pulsed with KRAS G12V or WT peptides were co-cultured with <t>CD8</t> + T cells in the presence of increasing concentrations (0, 0.1, 0.3, 1 and 10 nM) of scDb2. IFN-γ secretion was quantified by ELISpot assay. Data represent mean±SD of three technical replicates. The EC 50 for IFN-γ secretion was 0.59 nM for C1R-A11 cells. p=0.0023 at 0.3 nM and p<0.0001 at 1 and 10 nM versus KRAS WT (Tukey’s test). ( E ) KRAS peptide-specific T-cell activation by scDb2. C1R-A11 cells were pulsed with different KRAS G12 variant peptides (WT, G12A, G12C, G12D, G12R and G12S), then co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. IFN-γ secretion was measured by ELISpot. Data represent mean±SD of three technical replicates. p<0.0001 versus no peptide (Dunnett’s test). ( F ) HLA-restricted T-cell activation by scDb2. C1R cells expressing a panel of prevalent HLA-A alleles (HLA-A*02:01, HLA-A*02:06, HLA-A*03:01, HLA-A*11:01, HLA-A*24:02, HLA-A*31:01 and HLA-A*33:03) were pulsed with KRAS G12V peptide and co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. Data represent mean±SD of three technical replicates. p<0.0001 for HLA-A*11:01 and HLA-A*03:01 versus the no-peptide control; no significant differences were observed for the other HLA alleles versus the no-peptide control (Dunnett’s test). BsAb, bispecific antibody; EC 50 , half-maximal effective concentrations; ELISpot, enzyme-linked immunosorbent spot; HLA, human leukocyte antigen; IFN, interferon; scDb, single-chain diabody; WT, wild-type.
Anti Mouse Cd8 α, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd8/InVivoMAb+anti-mouse+CD8%CE%B2/pm42829916-411-4-19
Average 96 stars, based on 1 article reviews
anti mouse cd8 α - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

97
Bio X Cell anti cd8 antibody
BL828 modulates adaptive immune cell infiltration within the tumor microenvironment (A–J) Tumor samples were isolated after BL828 and vehicle treatment, and the immune infiltrating cells were analyzed by flow cytometry. (A) Representative flow cytometry panels and (B) percentages of CRTAM + NKGD2D + CD4 + T cells and CRTAM + NKG2D + CD4 + T cells expressing perforin (cytotoxic CD4 + T cells). (C) Representative flow cytometry panels and (D) relative percentages illustrating the percentage of IFN-γ + <t>CD8</t> + and proliferating Ki67 + CD8 + T cells infiltrating the 9464D tumor 35 days after tumor inoculation and BL828 or vehicle treatment ( n = 10). The statistical comparisons between tumor-infiltrating cell subpopulations were performed using unpaired t test. ∗ p < 0.05 ∗∗ p < 0.01. (E) Representative flow cytometry panels and percentages of CD4 + and CD8 + T cell depletion using anti-CD4 (clone GK1.5) or anti-CD8 (clone 2.43) depleting antibodies, or the corresponding isotype control antibody (IgG2a), on peripheral blood 2 days after the first antibody injection. (F) Mean tumor volume was monitored until day 32 after tumor inoculation ( n = 10 per group). (G) Individual tumor growth kinetics of 9464D-bearing mice treated with BL828 + anti-CD8 antibody. (H) Individual tumor growth kinetics of 9464D-bearing mice treated with BL828 + anti-CD4 antibody. (I) Individual tumor growth kinetics of 9464D-bearing mice treated with BL828 (2 mg/kg) + isotype control. The statistical comparisons between tumor volumes were performed using two-way ANOVA. ∗∗∗∗ p < 0.000.
Anti Cd8 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd8/InVivoMAb+anti-mouse+CD8%CE%B1/pmc13694809-340-31-35
Average 97 stars, based on 1 article reviews
anti cd8 antibody - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

93
Proteintech pe anti mouse cd8
BL828 modulates adaptive immune cell infiltration within the tumor microenvironment (A–J) Tumor samples were isolated after BL828 and vehicle treatment, and the immune infiltrating cells were analyzed by flow cytometry. (A) Representative flow cytometry panels and (B) percentages of CRTAM + NKGD2D + CD4 + T cells and CRTAM + NKG2D + CD4 + T cells expressing perforin (cytotoxic CD4 + T cells). (C) Representative flow cytometry panels and (D) relative percentages illustrating the percentage of IFN-γ + <t>CD8</t> + and proliferating Ki67 + CD8 + T cells infiltrating the 9464D tumor 35 days after tumor inoculation and BL828 or vehicle treatment ( n = 10). The statistical comparisons between tumor-infiltrating cell subpopulations were performed using unpaired t test. ∗ p < 0.05 ∗∗ p < 0.01. (E) Representative flow cytometry panels and percentages of CD4 + and CD8 + T cell depletion using anti-CD4 (clone GK1.5) or anti-CD8 (clone 2.43) depleting antibodies, or the corresponding isotype control antibody (IgG2a), on peripheral blood 2 days after the first antibody injection. (F) Mean tumor volume was monitored until day 32 after tumor inoculation ( n = 10 per group). (G) Individual tumor growth kinetics of 9464D-bearing mice treated with BL828 + anti-CD8 antibody. (H) Individual tumor growth kinetics of 9464D-bearing mice treated with BL828 + anti-CD4 antibody. (I) Individual tumor growth kinetics of 9464D-bearing mice treated with BL828 (2 mg/kg) + isotype control. The statistical comparisons between tumor volumes were performed using two-way ANOVA. ∗∗∗∗ p < 0.000.
Pe Anti Mouse Cd8, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd8/PE+Anti-mouse+CD8a/pm42785880-55-14-21
Average 93 stars, based on 1 article reviews
pe anti mouse cd8 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

95
Elabscience Biotechnology pe anti mouse cd8 alpha antibody
Overexpression of UPF1 in ccRCC inhibits M2 macrophage polarization and enhances the tumor suppressor function of <t>CD8</t> + T cells, Caki-1 cell groups of sh-NC+PBS, sh-UPF1+PBS, or sh-UPF1 + 2-DG, and the conditioned medium was used to culture and polarize M0 macrophages. The polarized macrophages were cultured with activated CD8 + T cells. (A) CFSE assessed CD8 + T cell proliferative capacity. (B) Flow cytometry measured apoptosis rate of CD8 + T cells in different co-culture systems. (C) CD8 + T cells from culture systems were co-cultured with normal Caki-1 cells, with LDH assays determining cytotoxic effect of CD8 + T cells. *, p < 0.05. cRCC, Clear cell renal cell carcinoma; UPF1, Up-frameshift protein 1; 2-DG, 2-Deoxy-D-glucose; CFSE, Carboxyfluorescein succinimidyl ester.
Pe Anti Mouse Cd8 Alpha Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd8/PE+Anti-Mouse+CD8a+Antibody/pmc13642288-120-47-53
Average 95 stars, based on 1 article reviews
pe anti mouse cd8 alpha antibody - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


( A ) In vivo tumor growth of RP-sgCtrl and RP-sg Crebbp cells in nude mice, with quantification of tumor weights at the endpoint (n = 6 per group). ( B ) In vivo tumor growth of RP-sgCtrl and RP-sg Crebbp cells in C57BL/6 mice, with quantification of tumor weights at the endpoint (n = 6 per group). ( C ) In vivo tumor growth of RP-shCtrl and RP-sh Crebbp cells in nude mice, with quantification of tumor weights at the endpoint (n = 5 per group). ( D ) In vivo tumor growth of RP-shCtrl and RP-sh Crebbp cells in C57BL/6 mice, with quantification of tumor weights at the endpoint (n = 4 for RP-shNS, n = 5 for each RP-sh Crebbp cell). ( E to G ) Flow cytometry analysis of CD8 + T cell proportions (E), CD44 hi CD62L lo CD8+ T cell proportions (F), and IFNγ + CD8 + T cell proportions (G) in allograft tumors formed by RP-sgCtrl and RP-sg Crebbp cells in C57BL/6 mice. n = 6 per group. ( H ) In vivo growth of RP-sgCtrl and RP-sg Crebbp cells in C57BL/6 mice treated with IgG control or anti-CD8 antibodies, with quantification of tumor weights at the endpoint (n = 5 per group). ( I ) Flow cytometry analysis of apoptotic RP-OVA, RP-OVA-shCtrl, and RP-OVA-sh Crebbp -1 tumor cells, with or without co-culture with OT-1 CD8 + T cells. Quantification of the apoptotic tumor cell proportions is shown (right). [(A), (B), (C), (D), and (H)] Two-way ANOVA test for tumor growth curves and unpaired Student’s t test for tumor weights. *** P < 0.001; **** P < 0.0001. ns, not significant. Data were shown as mean ± SEM. [(E) to (G) and (I)] Unpaired Student’s t test; * P < 0.05; ** P < 0.01. Data were shown as mean ± SD.

Journal: Science Advances

Article Title: CREBBP loss drives immune evasion by epigenetically silencing STING and MHC-I in small cell lung cancer

doi: 10.1126/sciadv.aef1693

Figure Lengend Snippet: ( A ) In vivo tumor growth of RP-sgCtrl and RP-sg Crebbp cells in nude mice, with quantification of tumor weights at the endpoint (n = 6 per group). ( B ) In vivo tumor growth of RP-sgCtrl and RP-sg Crebbp cells in C57BL/6 mice, with quantification of tumor weights at the endpoint (n = 6 per group). ( C ) In vivo tumor growth of RP-shCtrl and RP-sh Crebbp cells in nude mice, with quantification of tumor weights at the endpoint (n = 5 per group). ( D ) In vivo tumor growth of RP-shCtrl and RP-sh Crebbp cells in C57BL/6 mice, with quantification of tumor weights at the endpoint (n = 4 for RP-shNS, n = 5 for each RP-sh Crebbp cell). ( E to G ) Flow cytometry analysis of CD8 + T cell proportions (E), CD44 hi CD62L lo CD8+ T cell proportions (F), and IFNγ + CD8 + T cell proportions (G) in allograft tumors formed by RP-sgCtrl and RP-sg Crebbp cells in C57BL/6 mice. n = 6 per group. ( H ) In vivo growth of RP-sgCtrl and RP-sg Crebbp cells in C57BL/6 mice treated with IgG control or anti-CD8 antibodies, with quantification of tumor weights at the endpoint (n = 5 per group). ( I ) Flow cytometry analysis of apoptotic RP-OVA, RP-OVA-shCtrl, and RP-OVA-sh Crebbp -1 tumor cells, with or without co-culture with OT-1 CD8 + T cells. Quantification of the apoptotic tumor cell proportions is shown (right). [(A), (B), (C), (D), and (H)] Two-way ANOVA test for tumor growth curves and unpaired Student’s t test for tumor weights. *** P < 0.001; **** P < 0.0001. ns, not significant. Data were shown as mean ± SEM. [(E) to (G) and (I)] Unpaired Student’s t test; * P < 0.05; ** P < 0.01. Data were shown as mean ± SD.

Article Snippet: For CD8 + T cell blockade experiments, IgG1 isotype control (BE0088, Bio X Cell, RRID: AB_1107775) and anti-CD8 (BE0223, Bio X Cell, RRID: AB_2687706) antibodies were administered intraperitoneally at 100 μg per mouse one day before tumor cell inoculation, followed by a second dose immediately after cell injection, and then doses every 3 days.

Techniques: In Vivo, Flow Cytometry, Analysis, Control, Co-culture Assay, shRNA

Characterization of KRAS G12V-BsAb. ( A–B ) Selective binding of the purified scDb2 to KRAS G12V/HLA-A*11:01 ( A ) and CD3 ( B ) by ELISA. Biotinylated KRAS G12V/HLA-A*11:01 or recombinant CD3ε/δ was coated on a streptavidin plate and then incubated with scDb2 at 0.1, 1 or 10 nM, followed by detection with an anti-His antibody. Optical density at 450 nm was measured on a spectrophotometric plate reader. Data represent mean±SD of three technical replicates. ( C ) Surface plasmon resonance analysis of scDb2 binding to KRAS G12V/HLA-A*11:01 and KRAS WT/HLA-A*11:01. Binding kinetics were determined by fitting to a 1:1 Langmuir model. ( D ) Dose-dependent T-cell activation by scDb2. C1R-A11 cells pulsed with KRAS G12V or WT peptides were co-cultured with CD8 + T cells in the presence of increasing concentrations (0, 0.1, 0.3, 1 and 10 nM) of scDb2. IFN-γ secretion was quantified by ELISpot assay. Data represent mean±SD of three technical replicates. The EC 50 for IFN-γ secretion was 0.59 nM for C1R-A11 cells. p=0.0023 at 0.3 nM and p<0.0001 at 1 and 10 nM versus KRAS WT (Tukey’s test). ( E ) KRAS peptide-specific T-cell activation by scDb2. C1R-A11 cells were pulsed with different KRAS G12 variant peptides (WT, G12A, G12C, G12D, G12R and G12S), then co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. IFN-γ secretion was measured by ELISpot. Data represent mean±SD of three technical replicates. p<0.0001 versus no peptide (Dunnett’s test). ( F ) HLA-restricted T-cell activation by scDb2. C1R cells expressing a panel of prevalent HLA-A alleles (HLA-A*02:01, HLA-A*02:06, HLA-A*03:01, HLA-A*11:01, HLA-A*24:02, HLA-A*31:01 and HLA-A*33:03) were pulsed with KRAS G12V peptide and co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. Data represent mean±SD of three technical replicates. p<0.0001 for HLA-A*11:01 and HLA-A*03:01 versus the no-peptide control; no significant differences were observed for the other HLA alleles versus the no-peptide control (Dunnett’s test). BsAb, bispecific antibody; EC 50 , half-maximal effective concentrations; ELISpot, enzyme-linked immunosorbent spot; HLA, human leukocyte antigen; IFN, interferon; scDb, single-chain diabody; WT, wild-type.

Journal: Journal for Immunotherapy of Cancer

Article Title: Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01

doi: 10.1136/jitc-2026-016411

Figure Lengend Snippet: Characterization of KRAS G12V-BsAb. ( A–B ) Selective binding of the purified scDb2 to KRAS G12V/HLA-A*11:01 ( A ) and CD3 ( B ) by ELISA. Biotinylated KRAS G12V/HLA-A*11:01 or recombinant CD3ε/δ was coated on a streptavidin plate and then incubated with scDb2 at 0.1, 1 or 10 nM, followed by detection with an anti-His antibody. Optical density at 450 nm was measured on a spectrophotometric plate reader. Data represent mean±SD of three technical replicates. ( C ) Surface plasmon resonance analysis of scDb2 binding to KRAS G12V/HLA-A*11:01 and KRAS WT/HLA-A*11:01. Binding kinetics were determined by fitting to a 1:1 Langmuir model. ( D ) Dose-dependent T-cell activation by scDb2. C1R-A11 cells pulsed with KRAS G12V or WT peptides were co-cultured with CD8 + T cells in the presence of increasing concentrations (0, 0.1, 0.3, 1 and 10 nM) of scDb2. IFN-γ secretion was quantified by ELISpot assay. Data represent mean±SD of three technical replicates. The EC 50 for IFN-γ secretion was 0.59 nM for C1R-A11 cells. p=0.0023 at 0.3 nM and p<0.0001 at 1 and 10 nM versus KRAS WT (Tukey’s test). ( E ) KRAS peptide-specific T-cell activation by scDb2. C1R-A11 cells were pulsed with different KRAS G12 variant peptides (WT, G12A, G12C, G12D, G12R and G12S), then co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. IFN-γ secretion was measured by ELISpot. Data represent mean±SD of three technical replicates. p<0.0001 versus no peptide (Dunnett’s test). ( F ) HLA-restricted T-cell activation by scDb2. C1R cells expressing a panel of prevalent HLA-A alleles (HLA-A*02:01, HLA-A*02:06, HLA-A*03:01, HLA-A*11:01, HLA-A*24:02, HLA-A*31:01 and HLA-A*33:03) were pulsed with KRAS G12V peptide and co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A11:01-specific scDb2. Data represent mean±SD of three technical replicates. p<0.0001 for HLA-A*11:01 and HLA-A*03:01 versus the no-peptide control; no significant differences were observed for the other HLA alleles versus the no-peptide control (Dunnett’s test). BsAb, bispecific antibody; EC 50 , half-maximal effective concentrations; ELISpot, enzyme-linked immunosorbent spot; HLA, human leukocyte antigen; IFN, interferon; scDb, single-chain diabody; WT, wild-type.

Article Snippet: Sections were then incubated with primary antibodies: anti-CD8 mouse monoclonal antibody (Proteintech, Rosemont, Illinois, USA) and anti-Ki67 rabbit monoclonal antibody (Cell Signaling Technology, Danvers, Massachusetts, USA).

Techniques: Binding Assay, Purification, Enzyme-linked Immunosorbent Assay, Recombinant, Incubation, SPR Assay, Analysis, Activation Assay, Cell Culture, Enzyme-linked Immunospot, Variant Assay, Expressing, Control, ELISpot Assay

Assessment of KRAS G12V/A*11:01-specific scDb2 specificity and potential cross-reactivity. ( A ) Cross-reactivity of KRAS G12V variant peptides. C1R-A11 cells were pulsed with the parental KRAS G12V peptide or amino acid-substituted variants, and co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A*11:01-specific scDb2. IFN-γ release was measured by ELISpot assay, and the mean of duplicate wells was used to generate the heatmap. Black boxes indicate the amino acids present in the parental G12V peptide. ( B ) Sequence specificity of KRAS G12V/A*11:01 scDb2 visualized as a Seq2Logo plot. Values were calculated by normalizing IFN-γ signals to a constant and plotting using the R package Seq2Logo. ( C ) AlphaFold-predicted structure of the KRAS G12V-scFv2 in complex with KRAS G12V/HLA-A*11:01. HLA-A*11:01, scFv and β2 microglobulin (β2M) are colored in gray, wheat and cyan, respectively. The KRAS G12V peptide is shown in light red between helices α1 and α2 of the HLA. ( D ) Bird’s-eye view of surface representation of the HLA-A*11:01 shown in gray, KRAS G12V peptide shown in red, and the contacting residues colored according to complementarity-determining regions (CDRs) of the scFv. The CDRs are labeled and colored as: H3 (pink), H2 (purple), H1 (sky blue), L3 (green), L2 (limon), L1 (dark green). ELISpot, enzyme-linked immunosorbent spot; HLA, human leukocyte antigen; IFN, interferon; scDb, single-chain diabody; scFv, single-chain variable fragments; WT, wild-type.

Journal: Journal for Immunotherapy of Cancer

Article Title: Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01

doi: 10.1136/jitc-2026-016411

Figure Lengend Snippet: Assessment of KRAS G12V/A*11:01-specific scDb2 specificity and potential cross-reactivity. ( A ) Cross-reactivity of KRAS G12V variant peptides. C1R-A11 cells were pulsed with the parental KRAS G12V peptide or amino acid-substituted variants, and co-cultured with CD8 + T cells in the presence of 1 nM KRAS G12V/A*11:01-specific scDb2. IFN-γ release was measured by ELISpot assay, and the mean of duplicate wells was used to generate the heatmap. Black boxes indicate the amino acids present in the parental G12V peptide. ( B ) Sequence specificity of KRAS G12V/A*11:01 scDb2 visualized as a Seq2Logo plot. Values were calculated by normalizing IFN-γ signals to a constant and plotting using the R package Seq2Logo. ( C ) AlphaFold-predicted structure of the KRAS G12V-scFv2 in complex with KRAS G12V/HLA-A*11:01. HLA-A*11:01, scFv and β2 microglobulin (β2M) are colored in gray, wheat and cyan, respectively. The KRAS G12V peptide is shown in light red between helices α1 and α2 of the HLA. ( D ) Bird’s-eye view of surface representation of the HLA-A*11:01 shown in gray, KRAS G12V peptide shown in red, and the contacting residues colored according to complementarity-determining regions (CDRs) of the scFv. The CDRs are labeled and colored as: H3 (pink), H2 (purple), H1 (sky blue), L3 (green), L2 (limon), L1 (dark green). ELISpot, enzyme-linked immunosorbent spot; HLA, human leukocyte antigen; IFN, interferon; scDb, single-chain diabody; scFv, single-chain variable fragments; WT, wild-type.

Article Snippet: Sections were then incubated with primary antibodies: anti-CD8 mouse monoclonal antibody (Proteintech, Rosemont, Illinois, USA) and anti-Ki67 rabbit monoclonal antibody (Cell Signaling Technology, Danvers, Massachusetts, USA).

Techniques: Variant Assay, Cell Culture, Enzyme-linked Immunospot, Sequencing, Labeling, ELISpot Assay

In vivo antitumor efficacy of KRAS G12V-specific scDb2. ( A ) NSG mice were engrafted through s.c. injection with 5×10 6 SNG-M cells on day −7. On day 0, mice were randomized based on tumor sizes, and 2×10 7 human PBMCs or PBS as a vehicle control, and KRAS G12V-specific scDb2 or isotype control scDb (10 µg/mouse) were injected i.p. scDbs were subsequently injected two times per week. ( B ) Tumor progression was monitored by measuring tumor size. Data represent mean±SEM (n=8 mice/group). *p=0.043 PBMC+KRAS scDb2 versus PBMC+isotype scDb at the last time point (Tukey’s test). ( C ) Tumor weight of each mouse at the end of experiment was measured. Boxes show the median and IQR with individual mice plotted (n=8 mice/group). p values were calculated by Tukey’s test. ( D ) Representative H&E and multiplex immunohistochemical staining for CD8 and Ki67. Scale bars, 50 µm. ( E ) Proportion of CD8 + T cells and Ki67 + proliferating CD8 + T cells in tumors from each group. Data represent mean±SD (n=8 mice/group). p values were calculated by Tukey’s test. Scale bars, 10 µm. ( F ) Body weights of the mice were serially monitored in the established SNG-M model. Data represent mean±SEM (n=8 mice/group). (Tukey’s test, p=0.88 at the last time point). ( G ) Representative H&E staining of kidney and liver tissues from mice across treatment groups. Scale bars, 50 µm. i.p., intraperitoneally; NS, not significant; PBMC, peripheral blood mononuclear cells; PBS, phosphate buffered saline; s.c., subcutaneous; scDb, single-chain diabody.

Journal: Journal for Immunotherapy of Cancer

Article Title: Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01

doi: 10.1136/jitc-2026-016411

Figure Lengend Snippet: In vivo antitumor efficacy of KRAS G12V-specific scDb2. ( A ) NSG mice were engrafted through s.c. injection with 5×10 6 SNG-M cells on day −7. On day 0, mice were randomized based on tumor sizes, and 2×10 7 human PBMCs or PBS as a vehicle control, and KRAS G12V-specific scDb2 or isotype control scDb (10 µg/mouse) were injected i.p. scDbs were subsequently injected two times per week. ( B ) Tumor progression was monitored by measuring tumor size. Data represent mean±SEM (n=8 mice/group). *p=0.043 PBMC+KRAS scDb2 versus PBMC+isotype scDb at the last time point (Tukey’s test). ( C ) Tumor weight of each mouse at the end of experiment was measured. Boxes show the median and IQR with individual mice plotted (n=8 mice/group). p values were calculated by Tukey’s test. ( D ) Representative H&E and multiplex immunohistochemical staining for CD8 and Ki67. Scale bars, 50 µm. ( E ) Proportion of CD8 + T cells and Ki67 + proliferating CD8 + T cells in tumors from each group. Data represent mean±SD (n=8 mice/group). p values were calculated by Tukey’s test. Scale bars, 10 µm. ( F ) Body weights of the mice were serially monitored in the established SNG-M model. Data represent mean±SEM (n=8 mice/group). (Tukey’s test, p=0.88 at the last time point). ( G ) Representative H&E staining of kidney and liver tissues from mice across treatment groups. Scale bars, 50 µm. i.p., intraperitoneally; NS, not significant; PBMC, peripheral blood mononuclear cells; PBS, phosphate buffered saline; s.c., subcutaneous; scDb, single-chain diabody.

Article Snippet: Sections were then incubated with primary antibodies: anti-CD8 mouse monoclonal antibody (Proteintech, Rosemont, Illinois, USA) and anti-Ki67 rabbit monoclonal antibody (Cell Signaling Technology, Danvers, Massachusetts, USA).

Techniques: In Vivo, Injection, Control, Multiplex Assay, Immunohistochemical staining, Staining, Saline

BL828 modulates adaptive immune cell infiltration within the tumor microenvironment (A–J) Tumor samples were isolated after BL828 and vehicle treatment, and the immune infiltrating cells were analyzed by flow cytometry. (A) Representative flow cytometry panels and (B) percentages of CRTAM + NKGD2D + CD4 + T cells and CRTAM + NKG2D + CD4 + T cells expressing perforin (cytotoxic CD4 + T cells). (C) Representative flow cytometry panels and (D) relative percentages illustrating the percentage of IFN-γ + CD8 + and proliferating Ki67 + CD8 + T cells infiltrating the 9464D tumor 35 days after tumor inoculation and BL828 or vehicle treatment ( n = 10). The statistical comparisons between tumor-infiltrating cell subpopulations were performed using unpaired t test. ∗ p < 0.05 ∗∗ p < 0.01. (E) Representative flow cytometry panels and percentages of CD4 + and CD8 + T cell depletion using anti-CD4 (clone GK1.5) or anti-CD8 (clone 2.43) depleting antibodies, or the corresponding isotype control antibody (IgG2a), on peripheral blood 2 days after the first antibody injection. (F) Mean tumor volume was monitored until day 32 after tumor inoculation ( n = 10 per group). (G) Individual tumor growth kinetics of 9464D-bearing mice treated with BL828 + anti-CD8 antibody. (H) Individual tumor growth kinetics of 9464D-bearing mice treated with BL828 + anti-CD4 antibody. (I) Individual tumor growth kinetics of 9464D-bearing mice treated with BL828 (2 mg/kg) + isotype control. The statistical comparisons between tumor volumes were performed using two-way ANOVA. ∗∗∗∗ p < 0.000.

Journal: Molecular Therapy Oncology

Article Title: A novel spliceosome inhibitor triggers anti-tumor CD4 + and CD8 + T cell responses in murine models of pediatric-relevant cancer

doi: 10.1016/j.omton.2026.201355

Figure Lengend Snippet: BL828 modulates adaptive immune cell infiltration within the tumor microenvironment (A–J) Tumor samples were isolated after BL828 and vehicle treatment, and the immune infiltrating cells were analyzed by flow cytometry. (A) Representative flow cytometry panels and (B) percentages of CRTAM + NKGD2D + CD4 + T cells and CRTAM + NKG2D + CD4 + T cells expressing perforin (cytotoxic CD4 + T cells). (C) Representative flow cytometry panels and (D) relative percentages illustrating the percentage of IFN-γ + CD8 + and proliferating Ki67 + CD8 + T cells infiltrating the 9464D tumor 35 days after tumor inoculation and BL828 or vehicle treatment ( n = 10). The statistical comparisons between tumor-infiltrating cell subpopulations were performed using unpaired t test. ∗ p < 0.05 ∗∗ p < 0.01. (E) Representative flow cytometry panels and percentages of CD4 + and CD8 + T cell depletion using anti-CD4 (clone GK1.5) or anti-CD8 (clone 2.43) depleting antibodies, or the corresponding isotype control antibody (IgG2a), on peripheral blood 2 days after the first antibody injection. (F) Mean tumor volume was monitored until day 32 after tumor inoculation ( n = 10 per group). (G) Individual tumor growth kinetics of 9464D-bearing mice treated with BL828 + anti-CD8 antibody. (H) Individual tumor growth kinetics of 9464D-bearing mice treated with BL828 + anti-CD4 antibody. (I) Individual tumor growth kinetics of 9464D-bearing mice treated with BL828 (2 mg/kg) + isotype control. The statistical comparisons between tumor volumes were performed using two-way ANOVA. ∗∗∗∗ p < 0.000.

Article Snippet: Once tumors were established, mice were randomly divided into groups of 10 mice then T cell depletion was performed by intraperitoneal injection of anti-CD4 antibody (clone GK1.5, Bio X Cell) or anti-CD8 antibody (clone 2.43, Bio X Cell), respectively, at a dose of 200 μg per mouse.

Techniques: Immune Cell, Isolation, Flow Cytometry, Expressing, Control, Injection

Journal: Molecular Therapy Oncology

Article Title: A novel spliceosome inhibitor triggers anti-tumor CD4 + and CD8 + T cell responses in murine models of pediatric-relevant cancer

doi: 10.1016/j.omton.2026.201355

Figure Lengend Snippet:

Article Snippet: Once tumors were established, mice were randomly divided into groups of 10 mice then T cell depletion was performed by intraperitoneal injection of anti-CD4 antibody (clone GK1.5, Bio X Cell) or anti-CD8 antibody (clone 2.43, Bio X Cell), respectively, at a dose of 200 μg per mouse.

Techniques: Immunopeptidomics

Overexpression of UPF1 in ccRCC inhibits M2 macrophage polarization and enhances the tumor suppressor function of CD8 + T cells, Caki-1 cell groups of sh-NC+PBS, sh-UPF1+PBS, or sh-UPF1 + 2-DG, and the conditioned medium was used to culture and polarize M0 macrophages. The polarized macrophages were cultured with activated CD8 + T cells. (A) CFSE assessed CD8 + T cell proliferative capacity. (B) Flow cytometry measured apoptosis rate of CD8 + T cells in different co-culture systems. (C) CD8 + T cells from culture systems were co-cultured with normal Caki-1 cells, with LDH assays determining cytotoxic effect of CD8 + T cells. *, p < 0.05. cRCC, Clear cell renal cell carcinoma; UPF1, Up-frameshift protein 1; 2-DG, 2-Deoxy-D-glucose; CFSE, Carboxyfluorescein succinimidyl ester.

Journal: Frontiers in Immunology

Article Title: UPF1-dependent glycolysis driven by LINC00887 facilitates macrophage M2 polarization in clear cell renal cell carcinoma

doi: 10.3389/fimmu.2026.1833383

Figure Lengend Snippet: Overexpression of UPF1 in ccRCC inhibits M2 macrophage polarization and enhances the tumor suppressor function of CD8 + T cells, Caki-1 cell groups of sh-NC+PBS, sh-UPF1+PBS, or sh-UPF1 + 2-DG, and the conditioned medium was used to culture and polarize M0 macrophages. The polarized macrophages were cultured with activated CD8 + T cells. (A) CFSE assessed CD8 + T cell proliferative capacity. (B) Flow cytometry measured apoptosis rate of CD8 + T cells in different co-culture systems. (C) CD8 + T cells from culture systems were co-cultured with normal Caki-1 cells, with LDH assays determining cytotoxic effect of CD8 + T cells. *, p < 0.05. cRCC, Clear cell renal cell carcinoma; UPF1, Up-frameshift protein 1; 2-DG, 2-Deoxy-D-glucose; CFSE, Carboxyfluorescein succinimidyl ester.

Article Snippet: Antibodies included: FITC Mouse monoclonal to CD68 (ab134351, abcam, UK), Pacific Blue anti-human CD86 Antibody (305417, yajimall, China), CD206 (MMR) Monoclonal Antibody (19.2)-PE (12-2069-42, ThermoFisher, USA), PerCP/Cyanine5.5 Anti-Mouse F4/80 Antibody (E-AB-F0995J, Elabscience, China), PE Anti-CD206 mouse antibody (E-AB-F1135D, Elabscience, China), APC Anti-mouse CD3 antibody (E-AB-F1013E, Elabscience, China), PE Anti-mouse CD8 alpha antibody (E-AB-F1104D, Elabscience, China).

Techniques: Over Expression, Cell Culture, Flow Cytometry, Co-culture Assay

LINC00887/UPF1-mediated aerobic glycolysis leads to lactic acid accumulation and facilitates immune evasion in ccRCC in vivo , A syngeneic tumor model was developed by injecting BALB/c mice with Renca cells expressing sh-NC or sh-LINC00887, followed by treatment with sh-NC or sh-UPF1 lentivirus. A-C: Assessment of tumor size (A) , volume (B) , and weight (C) . (D, E) qRT-PCR analyses for LINC00887 (D) and UPF1 (E) mRNA levels. (F) IHC analysis for UPF1, LDH-A, KI67 protein levels. (G) Kit assay for lactate levels in tumors. (H) Proportion of M2 macrophages (F4/80+CD206+) by flow cytometry. (I) Immunofluorescence assay for CD206+ macrophages. (J) Proportion of CD8 + T cells (CD3 + CD8 + ) in tumor tissues. ns, no significant difference. * p < 0.05. cRCC, Clear cell renal cell carcinoma; UPF1, Up-frameshift protein 1; LDH-A, Lactate dehydrogenase A; CD206, Mannose receptor C-type 1; CD3, Cluster of differentiation 3; CD8, Cluster of differentiation 8.

Journal: Frontiers in Immunology

Article Title: UPF1-dependent glycolysis driven by LINC00887 facilitates macrophage M2 polarization in clear cell renal cell carcinoma

doi: 10.3389/fimmu.2026.1833383

Figure Lengend Snippet: LINC00887/UPF1-mediated aerobic glycolysis leads to lactic acid accumulation and facilitates immune evasion in ccRCC in vivo , A syngeneic tumor model was developed by injecting BALB/c mice with Renca cells expressing sh-NC or sh-LINC00887, followed by treatment with sh-NC or sh-UPF1 lentivirus. A-C: Assessment of tumor size (A) , volume (B) , and weight (C) . (D, E) qRT-PCR analyses for LINC00887 (D) and UPF1 (E) mRNA levels. (F) IHC analysis for UPF1, LDH-A, KI67 protein levels. (G) Kit assay for lactate levels in tumors. (H) Proportion of M2 macrophages (F4/80+CD206+) by flow cytometry. (I) Immunofluorescence assay for CD206+ macrophages. (J) Proportion of CD8 + T cells (CD3 + CD8 + ) in tumor tissues. ns, no significant difference. * p < 0.05. cRCC, Clear cell renal cell carcinoma; UPF1, Up-frameshift protein 1; LDH-A, Lactate dehydrogenase A; CD206, Mannose receptor C-type 1; CD3, Cluster of differentiation 3; CD8, Cluster of differentiation 8.

Article Snippet: Antibodies included: FITC Mouse monoclonal to CD68 (ab134351, abcam, UK), Pacific Blue anti-human CD86 Antibody (305417, yajimall, China), CD206 (MMR) Monoclonal Antibody (19.2)-PE (12-2069-42, ThermoFisher, USA), PerCP/Cyanine5.5 Anti-Mouse F4/80 Antibody (E-AB-F0995J, Elabscience, China), PE Anti-CD206 mouse antibody (E-AB-F1135D, Elabscience, China), APC Anti-mouse CD3 antibody (E-AB-F1013E, Elabscience, China), PE Anti-mouse CD8 alpha antibody (E-AB-F1104D, Elabscience, China).

Techniques: In Vivo, Expressing, Quantitative RT-PCR, Analysis, Flow Cytometry, Immunofluorescence